_id
695fb88ac2e91020a7bd4292
Ticker
0IIM.LSE
Name
Esperion Therapeutics, Inc.
Exchange
LSE
Address
3891 Ranchero Drive, Ann Arbor, MI, United States, 48108
Country
UK
Sector
Industry
Currency
USD
Website
https://www.esperion.com
Description
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company's marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. Its products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. It has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
Last Close
3.85
Volume
300
Current Price
3.85
Change
0.0007
Last Updated
2026-01-08T14:00:42.007Z
Ipo Date
-
Market Cap
12409084800
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
-
Sentiment Sources
0
Current Quarter
2025-09-30
Revenue
87309000
Cost Of Revenue
55420000
Gross Profit
31889000
Operating Expenses
41848000
Operating Income
-9959000
Interest Expense
22051000
Pretax Income
-31333000
Net Income
-31333000
Eps
-0.15812476513806806
Dividends Per Share
-
Shares Outstanding
26811000
Income Tax Expense
-
EBITDA
-9256000
Operating Margin
-11.406613293016758
Total Other Income Expense Net
-21374000
Cash
92447000
Short Term Investments
-
Receivables
118980000
Inventories
141838000
Total Current Assets
360464000
Property Plant Equipment
3500000
Total Assets
364020000
Payables
77513000
Short Term Debt
152073000
Long Term Debt
-
Total Liabilities
815381000
Equity
-451361000
Bs_currency_symbol
-
Depreciation
873000
Change In Working Capital
9700000
Cash From Operations
-4286000
Capital Expenditures
0
Cash From Investing
-
Cash From Financing
10672000
Net Change In Cash
6386000
Cf_currency_symbol
-
PE
-
PB
-1.6902026712542733
ROE
6.941893517605642
ROA
-8.607494093731113
FCF
-4286000
Fcf Percent
-0.0490900136297518
Piotroski FScore
1
Health Score
21
Deep Value Investing Score
1
Defensive Investing Score
7
Dividend Investing Score
1.5
Economic Moat Investing Score
4.3
Garp Investing Score
1.5
Growth Investing Score
1.5
Momentum Investing Score
2.5
Net Net Investing Score
0.5
Quality Investing Score
1
Value Investing Score
1.5
Quarters > 0 > quarter
2025-09-30
Quarters > 0 > income Statement > revenue
87309000
Quarters > 0 > income Statement > cost Of Revenue
55420000
Quarters > 0 > income Statement > gross Profit
31889000
Quarters > 0 > income Statement > operating Expenses
41848000
Quarters > 0 > income Statement > operating Income
-9959000
Quarters > 0 > income Statement > interest Expense
22051000
Quarters > 0 > income Statement > pretax Income
-31333000
Quarters > 0 > income Statement > net Income
-31333000
Quarters > 0 > income Statement > eps
-0.15812476513806806
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
198153654
Quarters > 0 > income Statement > income Tax Expense
-
Quarters > 0 > income Statement > EBITDA
-9256000
Quarters > 0 > income Statement > operating Margin
-11.406613293016758
Quarters > 0 > income Statement > total Other Income Expense Net
-21374000
Quarters > 0 > income Statement > currency_symbol
-
Quarters > 0 > balance Sheet > cash
92447000
Quarters > 0 > balance Sheet > short Term Investments
-
Quarters > 0 > balance Sheet > receivables
118980000
Quarters > 0 > balance Sheet > inventories
141838000
Quarters > 0 > balance Sheet > total Current Assets
360464000
Quarters > 0 > balance Sheet > property Plant Equipment
3500000
Quarters > 0 > balance Sheet > total Assets
364020000
Quarters > 0 > balance Sheet > payables
77513000
Quarters > 0 > balance Sheet > short Term Debt
152073000
Quarters > 0 > balance Sheet > long Term Debt
-
Quarters > 0 > balance Sheet > total Liabilities
815381000
Quarters > 0 > balance Sheet > equity
-451361000
Quarters > 0 > balance Sheet > currency_symbol
-
Quarters > 0 > cash Flow > net Income
-31333000
Quarters > 0 > cash Flow > depreciation
873000
Quarters > 0 > cash Flow > change In Working Capital
9700000
Quarters > 0 > cash Flow > cash From Operations
-4286000
Quarters > 0 > cash Flow > capital Expenditures
0
Quarters > 0 > cash Flow > cash From Investing
-
Quarters > 0 > cash Flow > cash From Financing
10672000
Quarters > 0 > cash Flow > net Change In Cash
6386000
Quarters > 0 > cash Flow > currency_symbol
-
Quarters > 0 > ratios > PE
-0.15812476513806806
Quarters > 0 > ratios > PB
-1.6902026712542733
Quarters > 0 > ratios > ROE
6.941893517605642
Quarters > 0 > ratios > ROA
-8.607494093731113
Quarters > 0 > ratios > FCF
-4286000
Quarters > 0 > ratios > Piotroski FScore
1
Quarters > 0 > ratios > fcf Percent
-0.0490900136297518
Quarters > 0 > health Score
21
Quarters > 1 > quarter
2025-06-30
Quarters > 1 > income Statement > revenue
82385000
Quarters > 1 > income Statement > cost Of Revenue
28543000
Quarters > 1 > income Statement > gross Profit
53842000
Quarters > 1 > income Statement > operating Expenses
46747000
Quarters > 1 > income Statement > operating Income
7095000
Quarters > 1 > income Statement > interest Expense
20486000
Quarters > 1 > income Statement > pretax Income
-12725000
Quarters > 1 > income Statement > net Income
-12725000
Quarters > 1 > income Statement > eps
-0.06464608491117196
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
196841000
Quarters > 1 > income Statement > income Tax Expense
-
Quarters > 1 > income Statement > EBITDA
7788000
Quarters > 1 > income Statement > operating Margin
8.612004612490137
Quarters > 1 > income Statement > total Other Income Expense Net
-19820000
Quarters > 1 > income Statement > currency_symbol
-
Quarters > 1 > balance Sheet > cash
86061000
Quarters > 1 > balance Sheet > short Term Investments
-
Quarters > 1 > balance Sheet > receivables
107746000
Quarters > 1 > balance Sheet > inventories
114466000
Quarters > 1 > balance Sheet > total Current Assets
342595000
Quarters > 1 > balance Sheet > property Plant Equipment
4434000
Quarters > 1 > balance Sheet > total Assets
347085000
Quarters > 1 > balance Sheet > payables
74704000
Quarters > 1 > balance Sheet > short Term Debt
123816000
Quarters > 1 > balance Sheet > long Term Debt
-
Quarters > 1 > balance Sheet > total Liabilities
780594000
Quarters > 1 > balance Sheet > equity
-433509000
Quarters > 1 > balance Sheet > currency_symbol
-
Quarters > 1 > cash Flow > net Income
-12725000
Quarters > 1 > cash Flow > depreciation
27000
Quarters > 1 > cash Flow > change In Working Capital
-26312000
Quarters > 1 > cash Flow > cash From Operations
-31422000
Quarters > 1 > cash Flow > capital Expenditures
0
Quarters > 1 > cash Flow > cash From Investing
-
Quarters > 1 > cash Flow > cash From Financing
2850000
Quarters > 1 > cash Flow > net Change In Cash
-28572000
Quarters > 1 > cash Flow > currency_symbol
USD
Quarters > 1 > ratios > PE
-0.06464608491117196
Quarters > 1 > ratios > PB
-1.748147904657112
Quarters > 1 > ratios > ROE
2.9353485164091175
Quarters > 1 > ratios > ROA
-3.6662489015658988
Quarters > 1 > ratios > FCF
-31422000
Quarters > 1 > ratios > Piotroski FScore
0
Quarters > 1 > ratios > fcf Percent
-0.38140438186563086
Quarters > 1 > health Score
17
Quarters > 2 > quarter
2025-03-31
Quarters > 2 > income Statement > revenue
64995000
Quarters > 2 > income Statement > cost Of Revenue
31538000
Quarters > 2 > income Statement > gross Profit
33457000
Quarters > 2 > income Statement > operating Expenses
55553000
Quarters > 2 > income Statement > operating Income
-22096000
Quarters > 2 > income Statement > interest Expense
19431000
Quarters > 2 > income Statement > pretax Income
-40455000
Quarters > 2 > income Statement > net Income
-40455000
Quarters > 2 > income Statement > eps
-0.20626841004832214
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
196127948
Quarters > 2 > income Statement > income Tax Expense
-
Quarters > 2 > income Statement > EBITDA
-20998000
Quarters > 2 > income Statement > operating Margin
-33.99646126625125
Quarters > 2 > income Statement > total Other Income Expense Net
-18359000
Quarters > 2 > income Statement > currency_symbol
-
Quarters > 2 > balance Sheet > cash
114633000
Quarters > 2 > balance Sheet > short Term Investments
-
Quarters > 2 > balance Sheet > receivables
81294000
Quarters > 2 > balance Sheet > inventories
99322000
Quarters > 2 > balance Sheet > total Current Assets
318778000
Quarters > 2 > balance Sheet > property Plant Equipment
5195000
Quarters > 2 > balance Sheet > total Assets
324029000
Quarters > 2 > balance Sheet > payables
71994000
Quarters > 2 > balance Sheet > short Term Debt
57492000
Quarters > 2 > balance Sheet > long Term Debt
-
Quarters > 2 > balance Sheet > total Liabilities
750240000
Quarters > 2 > balance Sheet > equity
-426211000
Quarters > 2 > balance Sheet > currency_symbol
-
Quarters > 2 > cash Flow > net Income
-40455000
Quarters > 2 > cash Flow > depreciation
725000
Quarters > 2 > cash Flow > change In Working Capital
12028000
Quarters > 2 > cash Flow > cash From Operations
-22628000
Quarters > 2 > cash Flow > capital Expenditures
0
Quarters > 2 > cash Flow > cash From Investing
-
Quarters > 2 > cash Flow > cash From Financing
-7500000
Quarters > 2 > cash Flow > net Change In Cash
-30128000
Quarters > 2 > cash Flow > currency_symbol
USD
Quarters > 2 > ratios > PE
-0.20626841004832214
Quarters > 2 > ratios > PB
-1.7716403372977234
Quarters > 2 > ratios > ROE
9.491777546801936
Quarters > 2 > ratios > ROA
-12.484993627113623
Quarters > 2 > ratios > FCF
-22628000
Quarters > 2 > ratios > Piotroski FScore
1
Quarters > 2 > ratios > fcf Percent
-0.3481498576813601
Quarters > 2 > health Score
23
Quarters > 3 > quarter
2024-12-31
Quarters > 3 > income Statement > revenue
69113000
Quarters > 3 > income Statement > cost Of Revenue
25631000
Quarters > 3 > income Statement > gross Profit
43482000
Quarters > 3 > income Statement > operating Expenses
47902000
Quarters > 3 > income Statement > operating Income
-4420000
Quarters > 3 > income Statement > interest Expense
16422000
Quarters > 3 > income Statement > pretax Income
-21318000
Quarters > 3 > income Statement > net Income
-21318000
Quarters > 3 > income Statement > eps
-0.109006167484893
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
195566916
Quarters > 3 > income Statement > income Tax Expense
-
Quarters > 3 > income Statement > EBITDA
-4869000
Quarters > 3 > income Statement > operating Margin
-6.395323600480372
Quarters > 3 > income Statement > total Other Income Expense Net
-16898000
Quarters > 3 > income Statement > currency_symbol
-
Quarters > 3 > balance Sheet > cash
144761000
Quarters > 3 > balance Sheet > short Term Investments
-
Quarters > 3 > balance Sheet > receivables
80142000
Quarters > 3 > balance Sheet > inventories
94491000
Quarters > 3 > balance Sheet > total Current Assets
337998000
Quarters > 3 > balance Sheet > property Plant Equipment
5767000
Quarters > 3 > balance Sheet > total Assets
343821000
Quarters > 3 > balance Sheet > payables
51650000
Quarters > 3 > balance Sheet > short Term Debt
57316000
Quarters > 3 > balance Sheet > long Term Debt
-
Quarters > 3 > balance Sheet > total Liabilities
732543000
Quarters > 3 > balance Sheet > equity
-388722000
Quarters > 3 > balance Sheet > currency_symbol
-
Quarters > 3 > cash Flow > net Income
-21318000
Quarters > 3 > cash Flow > depreciation
27000
Quarters > 3 > cash Flow > change In Working Capital
-21308000
Quarters > 3 > cash Flow > cash From Operations
-34952000
Quarters > 3 > cash Flow > capital Expenditures
0
Quarters > 3 > cash Flow > cash From Investing
-
Quarters > 3 > cash Flow > cash From Financing
34996000
Quarters > 3 > cash Flow > net Change In Cash
44000
Quarters > 3 > cash Flow > currency_symbol
USD
Quarters > 3 > ratios > PE
-0.109006167484893
Quarters > 3 > ratios > PB
-1.936943693950947
Quarters > 3 > ratios > ROE
5.484124901600629
Quarters > 3 > ratios > ROA
-6.200319352221069
Quarters > 3 > ratios > FCF
-34952000
Quarters > 3 > ratios > Piotroski FScore
0
Quarters > 3 > ratios > fcf Percent
-0.5057225124072172
Quarters > 3 > health Score
19
Annuals > 0 > quarter
2024-12-31
Annuals > 0 > income Statement > revenue
332314000
Annuals > 0 > income Statement > cost Of Revenue
68601000
Annuals > 0 > income Statement > gross Profit
263713000
Annuals > 0 > income Statement > operating Expenses
209311000
Annuals > 0 > income Statement > operating Income
54402000
Annuals > 0 > income Statement > interest Expense
59251000
Annuals > 0 > income Statement > pretax Income
-51745000
Annuals > 0 > income Statement > net Income
-51745000
Annuals > 0 > income Statement > eps
-0.2764423919378169
Annuals > 0 > income Statement > dividends Per Share
-
Annuals > 0 > income Statement > shares Outstanding
187181856
Annuals > 0 > income Statement > income Tax Expense
-
Annuals > 0 > income Statement > EBITDA
7569000
Annuals > 0 > income Statement > operating Margin
16.370661482814448
Annuals > 0 > income Statement > total Other Income Expense Net
-106147000
Annuals > 0 > income Statement > currency_symbol
-
Annuals > 0 > balance Sheet > cash
144761000
Annuals > 0 > balance Sheet > short Term Investments
-
Annuals > 0 > balance Sheet > receivables
80142000
Annuals > 0 > balance Sheet > inventories
94491000
Annuals > 0 > balance Sheet > total Current Assets
337998000
Annuals > 0 > balance Sheet > property Plant Equipment
5767000
Annuals > 0 > balance Sheet > total Assets
343821000
Annuals > 0 > balance Sheet > payables
51650000
Annuals > 0 > balance Sheet > short Term Debt
104902000
Annuals > 0 > balance Sheet > long Term Debt
-
Annuals > 0 > balance Sheet > total Liabilities
732543000
Annuals > 0 > balance Sheet > equity
-388722000
Annuals > 0 > balance Sheet > currency_symbol
-
Annuals > 0 > cash Flow > net Income
-51745000
Annuals > 0 > cash Flow > depreciation
63000
Annuals > 0 > cash Flow > change In Working Capital
-60530000
Annuals > 0 > cash Flow > cash From Operations
-23654000
Annuals > 0 > cash Flow > capital Expenditures
317000
Annuals > 0 > cash Flow > cash From Investing
-317000
Annuals > 0 > cash Flow > cash From Financing
86484000
Annuals > 0 > cash Flow > net Change In Cash
62513000
Annuals > 0 > cash Flow > currency_symbol
-
Annuals > 0 > ratios > PE
-0.2764423919378169
Annuals > 0 > ratios > PB
-1.8538959606093817
Annuals > 0 > ratios > ROE
13.311569707914654
Annuals > 0 > ratios > ROA
-15.049982403634449
Annuals > 0 > ratios > FCF
-23971000
Annuals > 0 > ratios > Piotroski FScore
0
Annuals > 0 > ratios > fcf Percent
-0.07213358450140529
Annuals > 0 > health Score
24
Annuals > 1 > quarter
2023-12-31
Annuals > 1 > income Statement > revenue
116334000
Annuals > 1 > income Statement > cost Of Revenue
43267000
Annuals > 1 > income Statement > gross Profit
73067000
Annuals > 1 > income Statement > operating Expenses
228630000
Annuals > 1 > income Statement > operating Income
-155563000
Annuals > 1 > income Statement > interest Expense
58976000
Annuals > 1 > income Statement > pretax Income
-209248000
Annuals > 1 > income Statement > net Income
-209248000
Annuals > 1 > income Statement > eps
-2.0294333003810348
Annuals > 1 > income Statement > dividends Per Share
-
Annuals > 1 > income Statement > shares Outstanding
103106616
Annuals > 1 > income Statement > income Tax Expense
-
Annuals > 1 > income Statement > EBITDA
-150108000
Annuals > 1 > income Statement > operating Margin
-133.721010194784
Annuals > 1 > income Statement > total Other Income Expense Net
-53685000
Annuals > 1 > income Statement > currency_symbol
-
Annuals > 1 > balance Sheet > cash
82248000
Annuals > 1 > balance Sheet > short Term Investments
-
Annuals > 1 > balance Sheet > receivables
48494000
Annuals > 1 > balance Sheet > inventories
65623000
Annuals > 1 > balance Sheet > total Current Assets
201065000
Annuals > 1 > balance Sheet > property Plant Equipment
4675000
Annuals > 1 > balance Sheet > total Assets
205796000
Annuals > 1 > balance Sheet > payables
31718000
Annuals > 1 > balance Sheet > short Term Debt
36381000
Annuals > 1 > balance Sheet > long Term Debt
-
Annuals > 1 > balance Sheet > total Liabilities
660790000
Annuals > 1 > balance Sheet > equity
-454994000
Annuals > 1 > balance Sheet > currency_symbol
-
Annuals > 1 > cash Flow > net Income
-209248000
Annuals > 1 > cash Flow > depreciation
164000
Annuals > 1 > cash Flow > change In Working Capital
13675000
Annuals > 1 > cash Flow > cash From Operations
-135487000
Annuals > 1 > cash Flow > capital Expenditures
0
Annuals > 1 > cash Flow > cash From Investing
42500000
Annuals > 1 > cash Flow > cash From Financing
50460000
Annuals > 1 > cash Flow > net Change In Cash
-42527000
Annuals > 1 > cash Flow > currency_symbol
USD
Annuals > 1 > ratios > PE
-2.0294333003810348
Annuals > 1 > ratios > PB
-0.8724521017859577
Annuals > 1 > ratios > ROE
45.98917787926874
Annuals > 1 > ratios > ROA
-101.67738925926646
Annuals > 1 > ratios > FCF
-135487000
Annuals > 1 > ratios > Piotroski FScore
0
Annuals > 1 > ratios > fcf Percent
-1.1646380249969914
Annuals > 1 > health Score
30
Annuals > 2 > quarter
2022-12-31
Annuals > 2 > income Statement > revenue
75475000
Annuals > 2 > income Statement > cost Of Revenue
26967000
Annuals > 2 > income Statement > gross Profit
48508000
Annuals > 2 > income Statement > operating Expenses
228009000
Annuals > 2 > income Statement > operating Income
-179501000
Annuals > 2 > income Statement > interest Expense
56810000
Annuals > 2 > income Statement > pretax Income
-233659000
Annuals > 2 > income Statement > net Income
-233659000
Annuals > 2 > income Statement > eps
-3.5185770853124723
Annuals > 2 > income Statement > dividends Per Share
-
Annuals > 2 > income Statement > shares Outstanding
66407242
Annuals > 2 > income Statement > income Tax Expense
-
Annuals > 2 > income Statement > EBITDA
-176349000
Annuals > 2 > income Statement > operating Margin
-237.8284200066247
Annuals > 2 > income Statement > total Other Income Expense Net
-54158000
Annuals > 2 > income Statement > currency_symbol
-
Annuals > 2 > balance Sheet > cash
124775000
Annuals > 2 > balance Sheet > short Term Investments
42086000
Annuals > 2 > balance Sheet > receivables
33729000
Annuals > 2 > balance Sheet > inventories
35201000
Annuals > 2 > balance Sheet > total Current Assets
246683000
Annuals > 2 > balance Sheet > property Plant Equipment
1200000
Annuals > 2 > balance Sheet > total Assets
247939000
Annuals > 2 > balance Sheet > payables
23040000
Annuals > 2 > balance Sheet > short Term Debt
384000
Annuals > 2 > balance Sheet > long Term Debt
-
Annuals > 2 > balance Sheet > total Liabilities
571717000
Annuals > 2 > balance Sheet > equity
-323778000
Annuals > 2 > balance Sheet > currency_symbol
-
Annuals > 2 > cash Flow > net Income
-233659000
Annuals > 2 > cash Flow > depreciation
500000
Annuals > 2 > cash Flow > change In Working Capital
-3373000
Annuals > 2 > cash Flow > cash From Operations
-174827000
Annuals > 2 > cash Flow > capital Expenditures
0
Annuals > 2 > cash Flow > cash From Investing
8104000
Annuals > 2 > cash Flow > cash From Financing
32606000
Annuals > 2 > cash Flow > net Change In Cash
-134117000
Annuals > 2 > cash Flow > currency_symbol
USD
Annuals > 2 > ratios > PE
-3.5185770853124723
Annuals > 2 > ratios > PB
-0.789639449561119
Annuals > 2 > ratios > ROE
72.16642267232486
Annuals > 2 > ratios > ROA
-94.24051883729466
Annuals > 2 > ratios > FCF
-174827000
Annuals > 2 > ratios > Piotroski FScore
0
Annuals > 2 > ratios > fcf Percent
-2.3163564094070885
Annuals > 2 > health Score
30
Annuals > 3 > quarter
2021-12-31
Annuals > 3 > income Statement > revenue
78447000
Annuals > 3 > income Statement > cost Of Revenue
14217000
Annuals > 3 > income Statement > gross Profit
64230000
Annuals > 3 > income Statement > operating Expenses
290960000
Annuals > 3 > income Statement > operating Income
-226730000
Annuals > 3 > income Statement > interest Expense
46353000
Annuals > 3 > income Statement > pretax Income
-269108000
Annuals > 3 > income Statement > net Income
-269108000
Annuals > 3 > income Statement > eps
-9.310887806376105
Annuals > 3 > income Statement > dividends Per Share
-
Annuals > 3 > income Statement > shares Outstanding
28902507
Annuals > 3 > income Statement > income Tax Expense
-
Annuals > 3 > income Statement > EBITDA
-222143000
Annuals > 3 > income Statement > operating Margin
-289.0231621349446
Annuals > 3 > income Statement > total Other Income Expense Net
-42378000
Annuals > 3 > income Statement > currency_symbol
-
Annuals > 3 > balance Sheet > cash
208892000
Annuals > 3 > balance Sheet > short Term Investments
50441000
Annuals > 3 > balance Sheet > receivables
22934000
Annuals > 3 > balance Sheet > inventories
34394000
Annuals > 3 > balance Sheet > total Current Assets
328972000
Annuals > 3 > balance Sheet > property Plant Equipment
2562000
Annuals > 3 > balance Sheet > total Assets
381590000
Annuals > 3 > balance Sheet > payables
17559000
Annuals > 3 > balance Sheet > short Term Debt
1392000
Annuals > 3 > balance Sheet > long Term Debt
-
Annuals > 3 > balance Sheet > total Liabilities
578534000
Annuals > 3 > balance Sheet > equity
-196944000
Annuals > 3 > balance Sheet > currency_symbol
-
Annuals > 3 > cash Flow > net Income
-269108000
Annuals > 3 > cash Flow > depreciation
612000
Annuals > 3 > cash Flow > change In Working Capital
-52513000
Annuals > 3 > cash Flow > cash From Operations
-263809000
Annuals > 3 > cash Flow > capital Expenditures
0
Annuals > 3 > cash Flow > cash From Investing
-50484000
Annuals > 3 > cash Flow > cash From Financing
268223000
Annuals > 3 > cash Flow > net Change In Cash
-46070000
Annuals > 3 > cash Flow > currency_symbol
USD
Annuals > 3 > ratios > PE
-9.310887806376105
Annuals > 3 > ratios > PB
-0.5650065599865952
Annuals > 3 > ratios > ROE
136.64188804939474
Annuals > 3 > ratios > ROA
-70.52281244267408
Annuals > 3 > ratios > FCF
-263809000
Annuals > 3 > ratios > Piotroski FScore
0
Annuals > 3 > ratios > fcf Percent
-3.3628946932323736
Annuals > 3 > health Score
30
Valuation > metrics > PE
-0.15812476513806806
Valuation > metrics > PB
-1.6902026712542733
Valuation > final Score
50
Valuation > verdict
Fair
Profitability > metrics > ROE
6.941893517605642
Profitability > metrics > ROA
-8.692407563584712
Profitability > metrics > Net Margin
-0.35887480099417013
Profitability > final Score
14
Profitability > verdict
Weak
Risk > metrics > Interest Coverage
-0.4516348464922226
Risk > final Score
28
Risk > verdict
High
Liquidity > metrics > Current Ratio
1.5700608922146821
Liquidity > metrics > Quick Ratio
0.9522618975024609
Liquidity > final Score
87
Liquidity > verdict
Great
Prev Valuations > 0
50
Prev Valuations > 1
50
Prev Valuations > 2
50
Prev Profitabilities > 0
6
Prev Profitabilities > 1
19
Prev Profitabilities > 2
11
Prev Risks > 0
31
Prev Risks > 1
25
Prev Risks > 2
29
Prev Liquidities > 0
93
Prev Liquidities > 1
100
Prev Liquidities > 2
100
Updated At
2026-01-20T23:13:35.564Z
Earnings History > 0 > period
2025-12-31
Earnings History > 0 > report Date
2026-03-03
Earnings History > 0 > date
2025-12-31
Earnings History > 0 > before After Market
BeforeMarket
Earnings History > 0 > currency
-
Earnings History > 0 > eps Actual
-
Earnings History > 0 > eps Estimate
0.28
Earnings History > 0 > eps Difference
0
Earnings History > 0 > surprise Percent
-
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company's marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. Its products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. It has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
Stock Price
$0.00
increase compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/AMP: CM Mohan Yadav Brings Bureaucrats With IIT, IIM, LSE Credentials To His Office Indian Masterminds
Read more →(Last Updated 2025-09-30)
Health Score
Price to Book Ratio (P/B)
-
Very Low
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Free Cash Flow - Revenue % (FCF)
-
Very Low
Low ≤ 5%
High ≥ 15%
* Institutions hold a combined 0.00% of the total shares of Esperion Therapeutics, Inc.
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
Date
2025-12-31
EPS Estimate
0.28
Date
—
EPS Actual
—
EPS Estimate
—
EPS Difference
—
Surprise Percent
undefined%
(Last Updated 2025-09-30)
(Last Updated 2025-09-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-09-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2025-09-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.